This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

E. S. Tolosa, MD
Dept of Neurology

S. B. Sparber, PhD
Dept of Pharmacology Univ of Minnesota Med School Minneapolis, MN 55455

Arch Neurol. 1977;34(1):58-59.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In a recent article in the ARCHIVES (33:517, 1976), we read the comments by Dr Kartzinel et al concerning some statements made by us on the effect of apomorphine hydrochloride on the chorea of Huntington disease.¹ The authors indicate that we propose that "hypersensitive striatal dopamine (postsynaptic) receptors may not constitute the basic disturbance of the striatal dopamine systems allegedly responsible for the chorea of Huntington Disease." As with the result observed by us with apomorphine, the findings by Dr Kartzinel and associates with bromocriptine support this interpretation. With doses of up to 40 mg/day of bromocriptine, no change in the choreiform movements of their Huntington disease patients occurred. Only higher, toxic doses aggravated the involuntary movements. Daily doses of bromocriptine of less than 40 mg induce chorea in patients with Parkinson disease² presumably through stimulation of "hypersensitive" striatal dopamine receptors. If in Huntington disease . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?